Program
vipoglanstat
Also written as “GS-248”, “Vipoglanstat” and “Formulation A GS-248”.
Its studies are mostly in Endometriosis · Scleroderma, Systemic, led by Gesynta Pharma AB.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gesynta Pharma AB | 41 open or running | phase 2since Jan 28, 2021 | Jul 23, 2019 | Jun 2027phase 2 · NCT07260669 |
Also a collaborator on its studies: ergomed and ctc-clinical-trial-consultants-ab.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 23, 2019First study: phase 1 study in HealthyFirst studyNCT04036227 · 72 enrolled · Sweden
- May 27, 2020Phase 1 study in PharmacokineticNCT04617509 · 14 enrolled · Sweden
- Jan 28, 2021Phase 2 study in Scleroderma, SystemicNCT04744207 · 94 enrolled · Belgium, Netherlands, Poland and more
- Sep 29, 2025Phase 2 study in EndometriosisNCT07260669 · 213 enrolled · Bulgaria, Czechia, Hungary and more
Ahead
- Jun 2027Primary completion: phase 2 study in EndometriosisNCT07260669
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07260669Endometriosis · Bulgaria, Czechia, Hungary and more | 2 | Active, not recruiting | Jun 2027 | 213 |
| NCT04744207Scleroderma, Systemic · Belgium, Netherlands, Poland and more | 2 | Completed | Jun 15, 2022 | 94 |
| NCT04617509Pharmacokinetic · Sweden | 1 | Completed | May 27, 2020 | 14 |
| NCT04036227Healthy · Sweden | 1 | Completed | Dec 20, 2019 | 72 |
How it is read
Names in the registry
- “GS-248”, 2 entries
- “Vipoglanstat”, 1 entry
- “Formulation A GS-248”, 1 entry
- “Formulation B GS-248”, 1 entry
Codes read as this program: GS248.
Conditions, from the studies’ own filings
- Endometriosis, 1 study
- Scleroderma, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.